TAAR1 emerges as a promising alternate target to GLP-1 for novel anti-diabetic, anti-obesity medications

Metabolic syndrome (MetS) affects over 30% of the global population, characterized by insulin resistance, obesity, and dyslipidaemia, significantly increasing the risk of type 2 diabetes mellitus (T2DM). Current antihyperglycaemic treatments often lose efficacy over time due to disease progression, necessitating novel therapeutic agents with diverse mechanisms. This highlights a critical gap for new approaches that can address both the physiological and neurobehavioral aspects of these complex metabolic disorders, moving beyond existing incretin-based therapies.

This chapter systematically reviewed emerging preclinical and clinical evidence on trace amine-associated receptor 1 (TAAR1) agonism, specifically focusing on its role as a regulator of metabolic function. The authors synthesized findings predominantly from studies investigating TAAR1's effects within the central nervous system for schizophrenia treatments, alongside its more recent exploration in metabolic contexts. A key aspect of the review involved direct comparisons of TAAR1's mechanisms with established incretin mimetic therapies, such as semaglutide (a GLP-1R agonist), to delineate mechanistic overlaps and potential therapeutic advantages for anti-diabetic and anti-obesity drug development.

The review highlights that trace amine-associated receptor 1 (TAAR1) activation significantly enhances glucose-stimulated insulin secretion, a crucial mechanism for blood glucose regulation. Beyond its direct metabolic effects, TAAR1 agonism also regulates dopaminergic pathways involved in addiction and reward processes, suggesting a dual benefit for both physiological and neurobehavioral aspects of metabolic disease. Comparisons with incretin mimetic therapies, including the GLP-1R agonist semaglutide, reveal substantial mechanistic overlap, indicating similar therapeutic potential in glucose homeostasis and weight management. However, the review also identifies potential advantages for TAAR1 activation, including a more favourable metabolic safety profile compared to existing GLP-1R agonists. This positions TAAR1 as a promising target capable of addressing the multifaceted challenges of Metabolic syndrome and T2DM.

Collectively, these findings suggest that TAAR1 agonism offers a novel approach to metabolic disease, potentially mitigating some limitations of current GLP-1R based treatments.